[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immunization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immunization":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,69,100,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100224513","influenza-immunization-in-adults-over-age-75-100224513",false,"NCT02200276","Influenza Immunization in Adults Over Age 75","Inclusion Criteria:\n\n* Adults over age 75 years\n\nExclusion Criteria:\n\n* Allergies to egg or vaccine\n* Active malignancies\n* On radiation or chemotherapy\n* Active systemic inflammatory diseases including rheumatoid arthritis, Crohn's disease, and ulcerative colitis\n* Acute exacerbation of chronic cardiopulmonary conditions including decompensated CHF or COPD\n* Taking oral steroids (such as prednisone) or immune modulating drugs (such as methotrexate).\n* Lacking the capacity to consent (individuals who do not understand what Flu shot is or need someone else to decide if s\u002Fhe should get the Flu shot)",true,"ALL","75 Years",{"count":19,"type":20},1025,"ESTIMATED","INTERVENTIONAL",[23],"NA","The immune system is the part of the body that protects against infection. The immune system often doesn't work as effectively as people get older. This research is being done to find out how the immune systems in older people who are over age 75 respond to influenza vaccine (flu shot). We also want to find out if chronic cytomegalovirus (CMV) infection, a common virus infection in older persons affects the immune response in people older than 75 years of age who receive a flu shot. The Flu Shot is a vaccine approved for the prevention of influenza (\"Flu\") infections and is recommended every year for all persons 50 years and older. People who are older than 75 years of age are considered healthy or frail may join. A total of 1025 persons will be participating in this study.\n\nIn order to determine if you are qualified for the study, we would ask you to answer a few questions over the phone that will take approximately 5 minutes. If you qualify and agree to proceed, you will be asked to come to Johns Hopkins Bayview Medical Center or, if you are unable to come to Bayview, one of our staff can visit you at your home. During that visit we obtain consent, review your medical history, and measure your vital signs, walking speed and grip strength. We will also administer a few brief questionnaires and collect urine and blood samples. We will then give you the Influenza vaccine for free. 7 days post receiving your Influenza Vaccine we will collect a small blood sample for further immune system testing. also, you will be asked to complete a 12-question survey which will assess your symptoms over the past 7 days (post receiving the Influenza vaccine). Also 4 weeks post receiving your Influenza vaccine you will be asked to complete a third visit that will include follow up health questionnaires and an influenza symptoms assessment questionnaire and vital signs. A third blood draw will be collected (approximately 10 teaspoons) to measure immune responses to the influenza vaccine. In addition, you will receive your test result (CBC\u002Fw\u002FDiff.) from visit #1. Throughout the influenza study season, we will call you once a week to ask about your general health and any Flu-like symptoms. These calls will be made throughout the Flu season which typically lasts through May. If you begin to have any influenza like symptoms at any time during the study, we ask that you call our office to report these symptoms so that we may perform vital signs, nasal swab to confirm influenza, and a fourth blood draw to look at the immune response and protection of influenza vaccine.",[26,27,28,29],"Influenza","Immunization","Older Adults","Over Age 75",[26],"RECRUITING","2026-03-13",{"date":34,"type":35},"2026-03-16","ACTUAL",{"date":37,"type":4},"2014-03",{"date":39,"type":20},"2027-11-30",{"name":41,"class":42},"Johns Hopkins University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":15,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":43},"100569421","post-marketing-surveillance-study-for-the-safety-of-efluelda-tetra-pre-filled-syringe-100569421","NCT06694025","Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.","Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe, a High-dose Quadrivalent Influenza Vaccine Administered to Adults 65 Years or Older in the Republic of Korea.","Inclusion Criteria:\n\n* Adults aged 65 years or older on the day of enrollment\n* The informed consent form has been signed and dated\n* Receipt of 1 dose of Efluelda Tetra on the day of enrollment according to the approved local product label\n\nExclusion Criteria:\n\n* Previous history of enrollment in this study\n* Participation at the time of study enrollment (or in the 4 weeks preceding the enrollment) or planned participation during the present study period in a clinical study investigating a vaccine, drug, medical device or medical procedure","65 Years",{"count":53,"type":20},670,"OBSERVATIONAL","To investigate the incidence of adverse events (AEs) and adverse drug reactions (ADRs) occurred following administration of Efluelda Tetra in adults aged 65 years or older under routine clinical practice, as per approved indications.\n\nThe study duration of each participation will be approximately 28 to 35 days. In the event that Visit 2 is not made, the study duration would be extended to 36 to 42 days.",[27,57],"Influenza (Healthy Volunteers)","NOT_YET_RECRUITING","2025-12-05",{"date":61,"type":35},"2025-12-15",{"date":63,"type":20},"2026-10-01",{"date":65,"type":20},"2028-01-31",{"name":67,"class":68},"Sanofi","INDUSTRY",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":15,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":43},"100490961","phase-4-comparing-immune-response-of-2-vs-3-hpv-doses-27-45-years-old-100490961","NCT05672927","Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)","Comparison of the Immune Response After Administration of 2 vs. 3 Doses of the FDA-approved 9-Valent HPV Vaccine Among Women 27-45 Years of Age","Inclusion criteria:\n\n1. Females 27-45 years old.\n2. Ability to give informed consent.\n3. Has not received any prior doses of the HPV vaccine. This will be verified by the person and state registry (Immtrac), as well as the person's electronic medical record.\n4. Reliable telephone access for the duration of the project.\n5. Can read and speak in either English or Spanish.\n6. Identified source of funding for vaccine such as Medicaid, private health insurance, Texas Healthy Women program, etc.\n7. Reports consistent use of reliable birth control and plans to continue its use through study month 13.\n\nExclusion criteria:\n\n1. Currently pregnant or plans to become pregnant or donate eggs in the next 13 months. Any subjects with positive pregnancy tests at the initial visit will be disqualified from the study and advised to seek prenatal care.\n2. Has an immunodeficiency or autoimmune disease such as HIV infection, lymphoma, leukemia, lupus, rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition.\n3. Currently receiving treatment or medication that can suppress immune function including radiation therapy, chemotherapy, cyclosporin, leflunomide (Arava), TNF-α antagonists, monoclonal antibody therapies (including rituximab \\[Rituxan\\]), intravenous gamma globulin (IVIG), antilymphocyte sera, other therapy known to interfere with the immune response, or systemic corticosteroids (by mouth or intramuscular injection). Those using or have used steroids that are inhaled, placed in the eye, applied on the skin, or injected into the joint\u002Fsoft tissue will be considered eligible for the study.\n4. History of splenectomy\n5. Known allergies to any vaccine components, including aluminum, yeast or Benzonase.\n6. Febrile at ≥100°F in the 24 hours prior to vaccination. The patients may be rescheduled for a later date.\n7. History of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.\n8. History of \\>10 sexual partners in their lifetime at time of enrollment\n9. Plans to move out of the Galveston\u002FHouston area in the 13 months following study entry.","FEMALE","27 Years","45 Years",{"count":80,"type":20},618,[82],"PHASE4","The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.",[27,85,86],"HPV Infection","Human Papillomavirus",[88,89,90],"HPV vaccination","Gardasil 9","Noninferiority trial","2025-10-02",{"date":93,"type":35},"2025-10-06",{"date":95,"type":35},"2023-01-18",{"date":97,"type":20},"2027-08",{"name":99,"class":42},"The University of Texas Medical Branch, Galveston",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":15,"sex":16,"minAge":107,"maxAge":51,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":43},"100571275","description-of-the-immune-response-to-yellow-fever-vaccination-100571275","NCT06718127","Description of the Immune Response to Yellow Fever Vaccination","IVORY2","Inclusion Criteria:\n\n* Age between 18 and 65\n* Referred for immunisation against yellow fever and typhoid\n* Any person with indication for the following vaccinations :\n* Yellow fever\n* Typhoïd\n* Whose vaccination schedule includes two appointments 7 days apart\n* Whose state of health is compatible with a single 51 ml blood sample collection\n* Have consented to participate in the Ivory2 study\n* Benefiting from a Social Security plan or equivalent\n\nExclusion Criteria:\n\n* Anyone with a contraindication to yellow fever and\u002For typhoid vaccination.\n* Any person who has been vaccinated against yellow fever and\u002For typhoid.\n* Anyone who has lived in an endemic area (≥ 1 year) and\u002For has a history of Typhoid.\n* Anyone who is unable to attend the visit 1-month after the typhoid vaccine injection.\n* Women claiming to be pregnant or breast-feeding\n* Anyone unable to give informed consent for participation","18 Years",{"count":109,"type":20},38,[23],"Vaccine protection depends on a specific adaptive immune memory. However, a little-explored aspect of certain live vaccines may provide beneficial, non-specific protection against infections or pathogens other than the one from which the vaccine is derived. This is the concept of innate immune memory or \" trained immunity\", which differs from adaptive memory in its non-specificity. Innate immune memory is triggered by exposure to immunostimulants, and offers protection against unrelated pathogenic threats for several months or even years.\n\nThe project aims to carry out an exploratory study to observe, in the context of current practice, the immune response obtained after a subunit and a live attenuated vaccine",[27,113],"Infections",[115,116],"immunology","Vaccine response","2025-06-27",{"date":119,"type":35},"2025-06-29",{"date":121,"type":35},"2024-09-30",{"date":123,"type":20},"2027-04-30",{"name":125,"class":68},"Institut Pasteur",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":15,"sex":16,"minAge":107,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":43},"100455625","adjuvant-effect-of-physical-exercise-on-immune-response-to-covid-19-vaccination-and-interactions-with-stress-100455625","NCT05213000","Adjuvant Effect of Physical Exercise on Immune Response to COVID-19 Vaccination and Interactions With Stress","The Effect of Health Behavioral Variables Including Single Session Exercise Post-immunization and Psychosocial Factors on Immune Response to the Initial COVID-19 mRNA Vaccine, and Underlying Mechanisms","Inclusion Criteria:\n\n* Able to donate a small amount of blood,\n* Planning to receive an initial mRNA Severe Acute Respiratory Distress Syndrome Coronavirus 2 vaccine,\n* Between 18-64 years of age,\n* Regularly participate in some form of exercise two or more times per week, including at least one session equal to or greater than 50 minutes exercise sessions or walk three or more times per week with at least one session equal to or greater than 50 minutes.\n* Can safely perform 90 minutes of light to moderate intensity exercise (walk, walk\u002Fjog, or jog) based on American College of Sports Medicine exercise participation guidelines\n\nExclusion Criteria:\n\n* Currently pregnant\n* Weigh less than 110 pounds.\n* Presence of any conditions that could significantly impact the ability to exercise safely, or unable to receive the mRNA COVID-19 vaccine\n* Taking medication that significantly impact immune response or the presence of an immune disorder.","64 Years",{"count":135,"type":20},80,[23],"The purpose of this study is to evaluate the extent to which a single session of light to moderate intensity exercise performed within 30 minutes after receiving either the initial dose of COVID-19 mRNA vaccine may modify the immune response to vaccination, and identify potential underlying mechanisms using gene expression and metabolite analysis. A secondary goal is to establish whether psychosocial factors are associated with immune response to vaccination. Participants will be randomized to either a 90-minute light to moderate intensity exercise session or daily routine as usual (no exercise) after receiving their initial COVID-19 mRNA vaccine. If assigned to exercise, the exercise will begin within 30 minutes after receiving the vaccine and will consist of a brisk walk and\u002For jog supervised by study personnel. Blood will be collected from participants prior the initial dose, two weeks after the initial dose, one week after the second dose if the individual receive the two-dose vaccine regiment or one month after the initial dose if the individual receives a one-dose vaccine regimen, and three, six, and 12 months following the initial dose. . Side effects will be measured for three days post-vaccination. Antibody and cell-mediated immune response to the vaccine will be measured in blood samples. Gene expression profiles will be analyzed by single cell RNA sequencing. Serum metabolites will be assessed to align with immune measures. Participants will be asked to complete surveys to measure physical activity history, psychosocial stress, resilience, and depression. The hypotheses of this study are: 1) a single session of exercise which take place shortly after receiving either the initial dose or the booster dose of COVID-19 will increase antibody and T cell response to the vaccine and will be associated with differentially expressed genes and an altered metabolite profile, and 2) higher levels of reported stress, and lower levels of resilience will be associated with a reduced antibody and T cell response to the vaccine.",[27],"2023-08-22",{"date":141,"type":35},"2023-08-24",{"date":143,"type":35},"2021-03-01",{"date":145,"type":20},"2026-09-30",{"name":147,"class":42},"Iowa State University"]